376 New South Head Road
Level 2
Double Bay, NSW 2028
Australia
61 2 9199 5018
https://bodscience.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Ms. Joanne Patterson | CEO, Executive Director & Member of Medical Advisory Board | 477.02k | N/A | N/A |
Mr. Adrian Sturrock | Chief Financial Officer | 377.63k | N/A | N/A |
Mr. Craig Weller | CTO & Member of Medical Advisory Board | 384.34k | N/A | N/A |
Dr. Adele Hosseini | Chief Scientific Officer & Member of Medical Advisory Board | N/A | N/A | N/A |
Mr. Alan Dworkin ACIS, BBus, CA | Advisor | N/A | N/A | N/A |
Ms. Carlie Hodges | Company Secretary | N/A | N/A | N/A |
Bod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States. The company operates through four segments: Medical, Over The Counter (OTC) Cannabidiol/Hemp, OTC Herbals, and Corporate. It engages in the development of cannabidiol and hemp products for consumers; and development and distribution of therapeutics medicinal cannabis products for medical markets. The company provides Flexofytol, an anti-inflammatory derived from a scientifically validated and clinically trialed turmeric extract that helps in improving joint pain and stiffness, joint health, limiting the ageing of cartilage, and reducing inflammation caused by mild arthritis; and Sedistress, a passion flower extract that reduces the symptoms of stress, anxiety, and insomnia, as well as contract manufacturing services. The company was formerly known as Bod Australia Limited and changed its name to Bod Science Limited in December 2022. Bod Science Limited was incorporated in 2014 and is based in Double Bay, Australia.
Bod Science Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.